Agios Pharmaceuticals Inc. (AGIO) Stock Price Down 2.3%
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares were down 2.3% during mid-day trading on Tuesday . The company traded as low as $36.75 and last traded at $36.90, with a volume of 339,728 shares trading hands. The stock had previously closed at $37.76.
A number of research analysts recently issued reports on AGIO shares. Vetr lowered Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $68.42 target price for the company. in a report on Tuesday, June 7th. JPMorgan Chase & Co. upgraded Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $50.00 to $62.00 in a report on Friday, June 10th. Janney Montgomery Scott reiterated a “neutral” rating and issued a $47.00 target price (down from $52.00) on shares of Agios Pharmaceuticals in a report on Monday, June 13th. Leerink Swann reiterated a “market perform” rating and issued a $56.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, May 19th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $50.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, June 9th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Agios Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $63.44.
The stock’s market cap is $1.39 billion. The company has a 50 day moving average price of $41.38 and a 200-day moving average price of $44.66.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.99. The business had revenue of $6.98 million for the quarter, compared to analysts’ expectations of $39.62 million. During the same quarter in the previous year, the business posted ($0.85) EPS. The firm’s quarterly revenue was down 47.2% on a year-over-year basis. On average, equities analysts forecast that Agios Pharmaceuticals Inc. will post ($5.02) EPS for the current fiscal year.
In other news, insider Scott Biller sold 27,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $65.00, for a total transaction of $1,787,500.00. Following the transaction, the insider now directly owns 81,376 shares in the company, valued at $5,289,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $42.80, for a total transaction of $107,171.20. Following the transaction, the director now owns 112,167 shares in the company, valued at $4,800,747.60. The disclosure for this sale can be found here.
Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.